Tissue Plasminogen Activator and MRI Signs of Cerebral Small Vessel Disease.
blood–brain barrier
cerebral small vessel disease
endothelial dysfunction
perivascular spaces
tissue plasminogen activator
white matter hyperintensities
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
05 Oct 2019
05 Oct 2019
Historique:
received:
08
09
2019
revised:
01
10
2019
accepted:
02
10
2019
entrez:
9
10
2019
pubmed:
9
10
2019
medline:
9
10
2019
Statut:
epublish
Résumé
Cerebral small vessel disease (SVD) is one of the leading causes of cognitive impairment and stroke. The importance of endothelial dysfunction and high blood-brain barrier (BBB) permeability in pathogenesis, together with ischemia, is under discussion. The aim of this study was to clarify the relationship between tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), and magnetic resonance imaging (MRI) signs of SVD. We examined 71 patients (23 men and 48 women; mean age: 60.5 ± 6.9 years) with clinical and MRI signs of SVD, and 21 healthy volunteers with normal MRIs. All subjects underwent 3T MRI and measurements of t-PA and PAI-1 levels. An increase in t-PA level is correlated with the volume of white matter hyperintensities (WMH) (
Identifiants
pubmed: 31590405
pii: brainsci9100266
doi: 10.3390/brainsci9100266
pmc: PMC6826933
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
J Clin Neurol. 2017 Apr;13(2):187-195
pubmed: 28406586
J Neurol. 2017 Jul;264(7):1474-1481
pubmed: 28653212
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Stroke. 2008 May;39(5):1414-20
pubmed: 18323505
Arch Neurol. 2001 Oct;58(10):1620-5
pubmed: 11594920
Stroke. 1997 Nov;28(11):2222-9
pubmed: 9368569
Stroke. 2010 Aug;41(8):1617-22
pubmed: 20595673
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973407
J Hypertens. 2013 Jul;31(7):1281-357
pubmed: 23817082
Lancet Neurol. 2013 May;12(5):483-97
pubmed: 23602162
J Am Coll Cardiol. 2001 Mar 1;37(3):871-7
pubmed: 11693764
Lab Invest. 2011 Jul;91(7):1079-91
pubmed: 21519332
Brain Res. 1997 Sep 5;767(2):259-64
pubmed: 9367256
Blood. 2012 May 17;119(20):4752-61
pubmed: 22262761
Thromb Haemost. 2014 Aug;112(2):243-54
pubmed: 24718307
Brain Res. 2014 May 27;1565:63-73
pubmed: 24675027
N Engl J Med. 1995 Dec 14;333(24):1581-7
pubmed: 7477192
Cardiovasc Res. 2018 Sep 1;114(11):1462-1473
pubmed: 29726891
J Cereb Blood Flow Metab. 2014 Aug;34(8):1283-96
pubmed: 24896566
PLoS One. 2016 Mar 04;11(3):e0150740
pubmed: 26942412
Neurology. 2017 Jun 13;88(24):2260-2267
pubmed: 28515266
J Pharmacol Sci. 2010;113(3):203-7
pubmed: 20595786
Semin Thromb Hemost. 2017 Mar;43(2):154-168
pubmed: 27677179
Alzheimers Dement (Amst). 2016 Jun 29;4:43-6
pubmed: 27489879
Int J Geriatr Psychiatry. 2018 Feb;33(2):325-331
pubmed: 28548298
Lancet Neurol. 2019 Jul;18(7):684-696
pubmed: 31097385
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
CNS Neurol Disord Drug Targets. 2008 Jun;7(3):243-53
pubmed: 18673209
Exp Biol Med (Maywood). 2004 Dec;229(11):1097-104
pubmed: 15564435
Stroke. 2005 Jul;36(7):1410-4
pubmed: 15905468